<DOC>
	<DOCNO>NCT00512889</DOCNO>
	<brief_summary>RATIONALE : Cytotoxic T lymphocytes ( CTL ) cell immune system fight infection cancer . These CTL manipulate laboratory target individual 's cancer . PURPOSE : This early phase trial study feasibility side effect intravenous infusion CTL generate laboratory . To produce CTL , study participant 's immune cell collect procedure call leukapheresis . The cell undergo laboratory processing three week . Part process include mixing patient immune cell new kind cell extra gene add . These extra gene `` teach '' participant 's immune cell become anti-tumor CTL attack melanoma .</brief_summary>
	<brief_title>Adoptive Transfer MART1/Melan-A CTL Malignant Melanoma</brief_title>
	<detailed_description>DETAILED OUTLINE : This early phase pilot/feasibility trial . Study subject sequentially accrue three cohort . Cohorts 1 2 evaluate safety feasibility infuse two different dos CTL . - Participants cohort undergo two CTL infusion 5 week apart . - Procedures perform trial include physical examination , laboratory test , delay hypersensitivity test , skin biopsy . - Between 5 8 day first CTL infusion , biopsy excision melanoma lesion may perform . - Three leukapheresis procedure perform : two collect peripheral blood CTL production one research purpose end clinical trial . - Radiology test ( include CT scan ) perform prior infusion 4-5 week second CTL infusion .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients metastatic melanoma : Either unresectable Stage III Stage IV ECOG 0 1 HLAA*0201 haplotype Baseline tumor biopsy MART1/MelanA expression present ( &gt; 10 % tumor cell ) Patient provide consent required biopsy Adequate intravenous access leukapheresis Absolute lymphocyte count &gt; 500/ul least within 30 day leukapheresis Life expectancy great 4 month opinion study clinician Negative pregnancy test Administration systemic corticosteroid within 28 day plan leukapheresis Administration cytotoxic chemotherapy antitumor immunotherapy within 28 day plan leukapheresis Administration radiotherapy within 28 day plan leukapheresis exception subject accrue Cohort 3 Active autoimmunity require systemic immunosuppressive therapy HIV infection Previous enrollment protocol infusion MART1/MelanA CTL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>CTL</keyword>
	<keyword>MART-1</keyword>
	<keyword>Melan-A</keyword>
	<keyword>artificial APC</keyword>
	<keyword>melanoma</keyword>
	<keyword>metastatic melanoma</keyword>
	<keyword>adoptive immunotherapy</keyword>
	<keyword>adoptive cell transfer</keyword>
	<keyword>immunotherapy</keyword>
</DOC>